Editorial abstract cover illustrating How to Choose a Healthcare Market Research Agency in Saudi Arabia: 10 Questions to Ask
    Market Research

    Questions to ask before you hire a research firm — A healthcare market research agency Saudi Arabia brief, in plain words

    I
    Ivona GunjovaGlobal Research Manager
    15 Oct 2026
    9 min
    Saudi Arabia
    Healthcare Market ResearchSaudi ArabiaMarket Research AgencySFDANUPCOCHIPDPLPrimary ResearchBuyer Guide
    Share:

    For the Kingdom buyer briefing, open the healthcare market research company in Saudi Arabia page, then the healthcare market research company hub for Saudi Arabia, the UAE and the GCC.

    A healthcare market research agency Saudi Arabia should field the study in the Kingdom. Start with the healthcare market research hub and the ranking of healthcare market research companies in Saudi Arabia.

    What this agency does

    It designs and fields commissioned research with physicians, pharmacists, payers, procurement leads, patients and caregivers. The usual decision is a formulary, a NUPCO tender, a CHI benefit, a launch forecast, or share of treated patients. Country context sits on healthcare market research in Saudi Arabia. The regional page is the healthcare market research agency GCC briefing.

    It is not a syndicated market-size PDF. Grand View Research and IMARC sell outlook pages. Those pages can sketch category spend. They cannot say which cluster will start a product. IQVIA, Ipsos and Kantar also sell custom work beside audits. Ask for the custom workstream, not the audit extract.

    Why the Kingdom is not a GCC average

    GASTAT’s mid-2024 estimate is 35.3 million residents, up 4.7% from mid-2023 (GASTAT publication; GASTAT statistics). The national portal prints 35,300,280 (my.gov.sa). Those are two published population files. Do not merge them. Saudis were 55.6% and non-Saudis 44.4%. Males were 62.1% (GASTAT).

    In 2023 the Kingdom had 113,300 medical doctors: 48,487 Saudi and 64,813 non-Saudi. The same file counts 72,261 male and 41,039 female doctors, 25,970 dentists, 213,110 nurses and 36,810 pharmacists (GASTAT). GASTAT counted 499 hospitals. Riyadh Region had 109. Makkah Region had 95. Beds were 23.8 per 10,000 population, 37.7 in the Northern Borders and 36.7 in Al-Baha (GASTAT). The Ministry of Health Statistical Yearbook is the regional cut (MOH yearbook page; Yearbook 2023 PDF).

    Vision 2030’s 2025 report records life expectancy of 79.7 years in 2024, primary-care coverage of 97.5%, and a Healthcare Quality Index of 70.4% in 2025, above a 60% target. The first phase launched 20 health clusters (Vision 2030 2025 report; annual-reports page). The Ministry of Health released the 2025 Health Sector Annual Report on 15 February 2026 (MOH, 15 February 2026). The programme report adds more than 31 million Sehati app beneficiaries (HSTP 2025).

    Illustration of the 2023 Saudi hospital count published by the statistics authority
    The 2023 healthcare-establishments file counts 499 hospitals, 23.8 beds per 10,000 people, and 113,300 doctors. A sample from one city is a city sample unless the brief asked for that city.

    The 10 questions

    Ask these before you award the study. A green answer names a place, a quota, a statute or a table. A red answer hides behind a GCC average.

    QuestionWhat a green answer namesWhat a red answer hides
    1. Fieldwork locationAl Khobar, Riyadh or Jeddah team; named subcontract“GCC coverage” from Dubai only
    2. RecruitmentSpecialty, sector, language, n per cellA convenience HCP panel with no quotas
    3. PDPL and ethicsController/processor roles; NCBE/IRB if charts“We follow GDPR” and nothing else
    4. Sample qualityVerification, replacement, ESOMAR 37 / ISO 20252Open-link CAWI with no identity check
    5. SplitsRegion, nationality, public / CHI / militaryOne national percentage
    6. Access layersSFDA, NUPCO, CHI, hospital P&T as four interviewsOne “payer” bucket
    7. MethodsPRF, IDI, CATI or CAWI tied to one decisionA syndicated market-size PDF
    8. Data ownershipClient-owned tables; PDPL transfer planAgency-owned panel that cannot be re-cut
    9. Written guaranteesMinimum n, replacement, re-field, credited pilotBest-efforts fieldwork and “indicative” n
    10. Therapy-area proofMethods pages and redacted instrumentsA logo wall of unnamed “pharma clients”

    Where the fieldwork runs

    Ask which team will book the interviews, and in which city. A named Al Khobar, Riyadh or Jeddah team, or a named subcontract, is a green answer. “GCC coverage” run only from Dubai is not a Kingdom sample. Physicians, payers and hospital committees do not share one diary.

    Ten numbered questions to ask a healthcare market research agency in Saudi Arabia before you brief
    Ten questions a 2026 healthcare market research agency Saudi Arabia brief should close: fieldwork, recruitment, PDPL, sample quality, splits, access layers, methods, data ownership, written guarantees and therapy-area proof.

    Who you can recruit

    Ask for specialty, sector, language and the n in each cell. Arabic and English instruments are both required. Physicians, pharmacists, payers and patients are four frames. A convenience panel with no quotas will not recover the hospital mix above.

    Health data and ethics

    Health data is Sensitive Data under the Personal Data Protection Law (PDPL). Article 23 adds controls. Article 29 sets conditions for a transfer outside the Kingdom. Article 36 can mean imprisonment of up to two years, or a fine of up to three million riyals, or both (PDPL). Article 26 of the Implementing Regulation covers documented processing of health data (Implementing Regulation). SDAIA publishes the law, the regulation and the transfer rules (SDAIA regulations), and a guide for controllers and processors (SDAIA guide).

    Chart review is a different gate. The National Committee of Bioethics oversees research on living creatures (NCBE; NCBE). Its standards page hosts the law, the implementing regulations and model consent forms (NCBE standards). “We follow GDPR” does not answer either gate.

    How sample quality is proved

    ESOMAR’s 37 questions replaced the 2012 list of 28 questions (ESOMAR 37; ESOMAR 28). The July 2025 ICC/ESOMAR code requires voluntary participation (ICC/ESOMAR). ISO 20252:2026 was published in September 2026. It does not cover direct marketing (ISO). Certification to the 2026 edition is mandatory from September 2029. Primary records are kept 12 months and project records 24 months, unless agreed otherwise (MRS). An open link with no identity check is not a sample plan.

    Council of Health Insurance Q3 2025 beneficiaries: 4.5 million Saudi and 9.5 million non-Saudi, of more than 14 million
    CHI announced more than 14 million private-insurance beneficiaries in the third quarter of 2025: 4.5 million Saudi and 9.5 million non-Saudi; 10 million primary subscribers and 4 million dependents. That is the insured private wallet, not the MOH or military wallet.

    Splits the tables must show

    Ask for region, nationality, and public versus CHI versus military. One national percentage hides the decision. CHI reported more than 13 million private-insurance beneficiaries on 7 January 2025 (CHI, 7 January 2025). A release dated 27 October 2025 reports more than 14 million in Q3 2025, of whom 4.5 million were Saudi and 9.5 million were non-Saudi (CHI, 27 October 2025). Do not average the two releases. People with private insurance are not the 35.3 million residents.

    SFDA, NUPCO and CHI are separate

    SFDA grants marketing authorisation (SFDA). NUPCO was founded in 2009, is fully owned by the Public Investment Fund, and has registered capital of SAR 1.5 billion (PIF; NUPCO). It buys pharmaceuticals, devices and supplies for government health entities (NUPCO services). CHI’s Essential Benefit Package took effect on 1 October 2022 (CHI EBP). The CHI formulary is an open list of SFDA-registered medicines. Addition requests go through a hospital Pharmacy and Therapeutics Committee or the assigned medical director (CHI formulary). PPRI describes SFDA pricing, NUPCO purchasing and hospital committees as separate steps (PPRI 2024). One “payer” interview is four missing interviews.

    Four Saudi access layers a healthcare market research agency must keep separate: SFDA, NUPCO, CHI and hospital P and T
    Four published access layers a healthcare market research agency in Saudi Arabia must keep separate: SFDA marketing authorisation, NUPCO unified government procurement, CHI private-insurance benefits and formulary, and each hospital Pharmacy and Therapeutics committee.

    Methods that fit the decision

    Tie the method to one decision. A prescribing diary, an interview, a phone survey or an online survey can each be right. A syndicated market-size PDF is not a method for a tender or a formulary. Say which instrument answers which question.

    Who owns the tables

    The client should own the tables and be able to re-cut them. State who is controller and who is processor, and how a transfer outside the Kingdom will meet Article 29. An agency-owned panel that cannot be re-cut is a red answer. Do not reuse respondent addresses for sales.

    What the written guarantee covers

    Ask what is guaranteed in writing before you compare fees. A usable line names the minimum sample, replacement of people who do not qualify, re-fielding if that sample is missed, and a pilot fee credited to the main study. That covers delivery. It does not cover what the interviews will find.

    Therapy-area proof

    Ask for named study types, a methods page and a redacted instrument. A logo wall of unnamed clients is not a credential. The example should match the decision you are buying, such as a tender, a formulary or a treated-patient share.

    Red amber green scorecard for scoring a Saudi healthcare market research agency proposal
    Score the proposal against the questions on this page. A syndicated market-size slide is not in-Kingdom fieldwork.

    How to use the list

    Use the ten questions when you decide how to choose a healthcare market research agency. Score the proposal on fieldwork city, recruitment quotas, health-data roles, sample checks, the three access bodies, data ownership and the written guarantee. Drop any bid that offers one national percentage.

    How to brief BioNixus

    BioNixus is a primary market research firm for pharmaceutical, medical device and healthcare companies. It was founded in 2012. It has served 118 clients in 48 countries. It has run 127 studies so far in 2026. It works with a network of 82,000+ physicians globally and about 3,200 physicians in the Middle East. Custom studies are usually priced at $10k–$60k. Leadership offices are in Sheridan, Wyoming, London EC1V 2NX, and Sheikh Zayed, Giza. There are a field office for UAE in Dubai, a partner office for KSA in Al Khobar, and a field office for Kuwait in Salmiya. São Paulo is a field office for LATAM. Work in Latin America is covered today from the US office with local consultants.

    The line “Guaranteed in writing” covers scope, timing, replacement of respondents who do not qualify, the minimum sample, re-fielding if that sample is missed, and a credited pilot. It does not cover what the interviews will find. BioNixus has 40 client reviews.

    Use the contact form or email admin@bionixus.com.

    References

    1. General Authority for Statistics (GASTAT). Population Estimates Statistics 2024 (English). Mid-2024 estimate: 35.3 million residents. Source (accessed 15 October 2026).
    2. GASTAT. Population Estimates Publication 2024 (English PDF). Total population 35.3 million in mid-2024; annual growth 4.7% versus mid-2023. Source (accessed 15 October 2026).
    3. National Platform (my.gov.sa). Reports and Statistics: population in 2024 listed as 35,300,280. Source (accessed 15 October 2026).
    4. GASTAT. Healthcare Establishments and Workforce Statistics Publication 2023. 499 hospitals; 23.8 beds per 10,000 population; 113,300 medical doctors (48,487 Saudi; 64,813 non-Saudi). Source (accessed 15 October 2026).
    5. Ministry of Health. Statistical Yearbook landing page. Yearbook 2023 PDF and 2024 Excel listed as available downloads. Source (accessed 15 October 2026).
    6. Ministry of Health. Statistical Yearbook 2023 (English/Arabic PDF). Hospitals, beds and health-manpower tables by health region, nationality and specialty. Source (accessed 15 October 2026).
    7. Council of Health Insurance (CHI). More than 13 million beneficiaries of private health-insurance services in the Kingdom. News release, 7 January 2025. Source (accessed 15 October 2026).
    8. CHI. 14 million beneficiaries of private health-insurance services in the Kingdom. News release, 27 October 2025. More than 14 million in Q3 2025; 10 million primary subscribers and 4 million dependents; 4.5 million Saudi and 9.5 million non-Saudi. Source (accessed 15 October 2026).
    9. CHI. Basic Health Insurance Policy: Updated Essential Benefit Package (effective 1 October 2022). Source (accessed 15 October 2026).
    10. CHI. CHI Drug Formulary (Dhaman). Open formulary of SFDA-registered medicines; addition requests go through a hospital Pharmacy and Therapeutics Committee or the assigned medical director. Source (accessed 15 October 2026).
    11. NUPCO. Overview. Founded in 2009 and fully owned by the Public Investment Fund; unified procurement, warehousing and distribution of pharmaceuticals, medical devices and supplies for government health entities. Source (accessed 15 October 2026).
    12. Public Investment Fund. The National Unified Procurement Company (nupco). Established 2009; registered capital SAR 1.5 billion; fully owned by PIF. Source (accessed 15 October 2026).
    13. NUPCO. Services and business solutions: unified procurement of pharmaceuticals, medical supplies and healthcare equipment through consolidated sourcing and demand aggregation. Source (accessed 15 October 2026).
    14. Saudi Vision 2030. Annual Report 2025 (English PDF). Life expectancy 79.7 years in 2024; primary-care coverage 97.5%; Healthcare Quality Index 70.4% in 2025; first phase of health-sector transformation completed with the launch of 20 health clusters. Source (accessed 15 October 2026).
    15. Saudi Vision 2030. 2025 Annual Report landing page. Healthcare coverage listed at 97.5%. Source (accessed 15 October 2026).
    16. Health Sector Transformation Program. Annual Report 2025 (Arabic PDF). Life expectancy 79.7 years; primary-care coverage 97.5%; more than 31 million Sehati (Sehhaty) app beneficiaries. Source (accessed 15 October 2026).
    17. Ministry of Health. Ministry of Health Releases the 2025 Health Sector Annual Report. 15 February 2026. Source (accessed 15 October 2026).
    18. Saudi Data & Artificial Intelligence Authority (SDAIA). Personal Data Protection Law (English translation). Health Data is Sensitive Data (Article 1). Additional health-data controls in Article 23. Cross-border transfer conditions in Article 29. Disclosure or publication of Sensitive Data in violation of the Law can carry imprisonment of up to two years or a fine of up to three million riyals, or both (Article 36). Source (accessed 15 October 2026).
    19. SDAIA. Implementing Regulation of the Personal Data Protection Law (English). Article 26 (Processing Health Data) requires documented processing, role-based access, processor-contract clauses and minimum-necessary processing. Source (accessed 15 October 2026).
    20. SDAIA. Guide to the Saudi Personal Data Protection Law for controllers and processors (English). Source (accessed 15 October 2026).
    21. SDAIA. Laws and regulations page: Personal Data Protection Law, Implementing Regulation, and Regulation on Personal Data Transfer Outside the Kingdom. Source (accessed 15 October 2026).
    22. ICC / ESOMAR. International Code on Market, Opinion and Social Research and Data Analytics (updated July 2025): participation is voluntary and based on clear information; re-contact needs agreement except for quality control, adverse-event reporting or law; consent is a freely given, specific and informed indication of agreement. Source (accessed 15 October 2026).
    23. ESOMAR. 37 Questions to Help Buyers of Online Samples. Official publication page; updates and replaces the 2012 “28 Questions” document. Source (accessed 15 October 2026).
    24. ESOMAR. 28 Questions to Help Buyers of Online Samples (September 2012 PDF). Predecessor buyer checklist for online sample sources, recruitment and quality controls. Source (accessed 15 October 2026).
    25. International Organization for Standardization. ISO 20252:2026, Market, opinion and social research, including insights and data analytics — Vocabulary and service requirements. Edition 4, published September 2026. Does not apply to non-research activities such as direct marketing. Source (accessed 15 October 2026).
    26. Market Research Society. Quality standards: ISO 20252:2026 replaces ISO 20252:2019; three-year transition, with certification to the 2026 standard mandatory from September 2029. Primary records retained for 12 months (or as agreed); project research records for 24 months (or as agreed). Source (accessed 15 October 2026).
    27. PPRI / Austrian National Public Health Institute. Healthcare system and pharmaceutical pricing in Saudi Arabia (2024). Describes SFDA pricing, NUPCO group purchasing, hospital Pharmacy and Therapeutics committees, and Council of Health Insurance control of private reimbursement. Source (accessed 15 October 2026).
    28. National Committee of Bioethics (NCBE). Public website and researcher portal for ethical review of research on living creatures. Source (accessed 15 October 2026).
    29. NCBE. Who We Are. The National Committee sets standards for biological research ethics, oversees local committees, and sets ethical controls to safeguard rights of human subjects and confidentiality of research information. Source (accessed 15 October 2026).
    30. NCBE. Standards and Regulations. Hosts the Law of Ethics of Research on Living Creatures, its Implementing Regulations, and model informed-consent forms. Source (accessed 15 October 2026).
    31. Saudi Food and Drug Authority (SFDA). English home page. SFDA is the competent authority for marketing authorisation of medicines, medical devices and other regulated products in the Kingdom. Source (accessed 15 October 2026).
    32. IQVIA. Global healthcare data, analytics and contract-research group. Syndicated audits and custom consulting are different products; a Saudi custom brief is not an IMS/MIDAS extract. (accessed 15 October 2026).
    33. Ipsos. Global insights group with a healthcare practice. Public “ESOMAR 37” sample-provider answers describe online-sample operations, not a Saudi in-clinic hematology or payer study. (accessed 15 October 2026).
    34. Kantar. Global insights group; Kantar Health / Cerner Enviza heritage is often cited on GCC healthcare RFPs. A brand-tracker methodology is not a NUPCO or CHI access study. (accessed 15 October 2026).
    35. Grand View Research. Syndicated country and therapy-area outlook pages. Useful for a first cut of category spend; not a substitute for primary physician, patient or payer research. (accessed 15 October 2026).
    36. IMARC Group. Syndicated Saudi healthcare and pharmaceutical report pages. Desk-research market-size documents, not commissioned fieldwork. (accessed 15 October 2026).

    Explore related research

    For deeper regional insight, explore our healthcare market research framework and country coverage.

    Explore BioNixus capabilities & hubs

    Directory of every indexed marketing destination — GCC and MENA research pages, localized hubs, methodologies, pharmaceutical directories, reports, global websites, insights, case studies, methodology, and Arabic coverage. Prefer this index over generic “related” lists for full-site context.

    12 groups · 265 URLs

    Full structured sitemap
    Home & language hubsLocalized entry points for BioNixus.5
    Company, trust & methodologyAbout, contact, compliance, and how we work.28
    Core servicesQuantitative, qualitative, access, intelligence, trials, KOL.3
    Healthcare market research hubCountries, cities, therapy areas, and research modules.57
    GCC, MENA & specialty programsPillar landings, alternatives, and deep-dive reports.36
    Pharmaceutical company directoriesCountry-level industry snapshots.9
    Healthcare & devices market reportsGCC and country medical market briefs.1
    Blog & insightsEditorial briefs, guides, and regional analysis.80
    Case studiesSelected client evidence and programme outcomes.5
    Portfolio & conferenceStrategic portfolio deck and event pages.2
    Localized pagesMarket access, contacts, and market research by locale.6
    Additional pagesSupporting URLs and tooling.33

    FAQFrequently asked questions

    What is a healthcare market research agency Saudi Arabia?
    A firm that fields commissioned interviews with physicians, pharmacists, payers and patients in the Kingdom, for one decision. It is not a syndicated market-size report.
    How do I choose a healthcare market research agency in Saudi Arabia?
    Ask where the fieldwork runs, who recruits, how health data are handled, and what is guaranteed in writing. Split results by region, nationality and payer. Treat SFDA, NUPCO and CHI as separate decisions.
    Does a healthcare market research agency in Saudi Arabia need a local office?
    Ask for an in-Kingdom team or a named subcontract in Al Khobar, Riyadh or Jeddah. A slide that says GCC coverage from Dubai only is not a Kingdom sample.
    What does PDPL mean for healthcare interviews in Saudi Arabia?
    Health data is Sensitive Data. Article 23 adds controls. Article 26 of the Implementing Regulation covers processing. Article 36 can mean up to two years or a fine of up to three million riyals.
    How is NUPCO different from CHI for research design?
    NUPCO, founded in 2009 and owned by the Public Investment Fund, buys for government health entities. CHI runs private insurance and the Essential Benefit Package. A tender interview is not a formulary interview.
    What should a healthcare market research proposal guarantee in writing?
    A minimum sample, replacement of people who do not qualify, re-fielding if that sample is missed, and a credited pilot. That covers delivery. It does not cover what the interviews will find.
    Why commission BioNixus for healthcare market research in Saudi Arabia?
    Custom studies run from the Al Khobar field office, with a network of 82,000+ physicians globally and about 3,200 physicians in the Middle East, usually at $10k–$60k. Guaranteed in writing covers scope and sample. It does not cover what the interviews will find.

    Expert Consultation

    Choosing a healthcare market research agency in Saudi Arabia?

    Tell us the Saudi decision you need to make. BioNixus scopes the study around that decision. Custom work is usually $10k–$60k.

    Talk to BioNixus
    I

    Research Author

    Ivona Gunjova

    Global Research Manager

    Related Articles

    Saudi hematology diagnostics reports count analyzers. Pharma still needs the ward-level brand cut.
    Healthcare Market Research
    Saudi Arabia15 Nov 2026

    Saudi hematology diagnostics reports count analyzers. Pharma still needs the ward-level brand cut.

    Saudi hematology diagnostics reports size analyzers and reagents. They do not show which ward is moving medicine share. Here is the cut primary research still has to make.

    Read article
    Syndicated Saudi diabetes numbers size the category. They still miss which hospital is switching.
    Healthcare Market Research
    Saudi Arabia15 Nov 2026

    Syndicated Saudi diabetes numbers size the category. They still miss which hospital is switching.

    Syndicated Saudi diabetes reports size the category. They do not show which hospital is switching. Here is what primary research still has to answer.

    Read article
    AstraZeneca Brings CRISPR Gene-Editing Research to Saudi Arabia: What the KAIMRC Programme Is, and Is Not
    Healthcare Market Research
    Saudi Arabia9 Nov 2026

    AstraZeneca Brings CRISPR Gene-Editing Research to Saudi Arabia: What the KAIMRC Programme Is, and Is Not

    AstraZeneca and KAIMRC are running preclinical CRISPR research on ASL deficiency in Saudi Arabia, with training for up to 12 Saudi scientists. What is confirmed and what to research next.

    Read article
    Avalon Pharma Signs for a Generic Mounjaro in Saudi Arabia Before It Can Launch One
    Healthcare Market Research
    Saudi Arabia5 Nov 2026

    Avalon Pharma Signs for a Generic Mounjaro in Saudi Arabia Before It Can Launch One

    Avalon Pharma licensed a generic Mounjaro KwikPen (tirzepatide) from OneSource for Saudi Arabia and MENA. What it means for GLP-1 and obesity teams.

    Read article
    EVA Pharma's TriGutirek XR Puts a Triple Diabetes Tablet into Saudi Pharmacies. Here Is What Market Access Teams Should Check Next
    Healthcare Market Research
    Saudi Arabia4 Nov 2026

    EVA Pharma's TriGutirek XR Puts a Triple Diabetes Tablet into Saudi Pharmacies. Here Is What Market Access Teams Should Check Next

    EVA Pharma's TriGutirek XR (empagliflozin/linagliptin/metformin XR) is described as the first triple FDC of these actives approved in Saudi Arabia. Cigalah and United Pharmacies deals, SFDA listing no

    Read article

    Planning research in Saudi Arabia?

    Primary research, market access & HEOR. A 30-minute scoping call, then a costed proposal within 48 hours.

    What happens on the call

    • We pin down the decision your research has to support.
    • We check feasibility: respondent types, countries and timeline.
    • You receive a costed proposal within 48 hours of the call.